keyword
MENU ▼
Read by QxMD icon Read
search

Menopausal hormonal therapy

keyword
https://www.readbyqxmd.com/read/29782643/lifetime-number-of-years-of-menstruation-as-a-risk-index-for-postmenopausal-endometrial-cancer-in-the-norwegian-women-and-cancer-study
#1
Oxana Gavrilyuk, Tonje Braaten, Elisabete Weiderpass, Idlir Licaj, Eiliv Lund
INTRODUCTION: Lifetime number of years of menstruation (LNYM) reflects a woman's cumulative exposure to endogenous estrogen and can be used as a measure of the combined effect of reproductive factors related to endometrial cancer (EC) risk. MATERIAL AND METHODS: We aimed to study the association between LNYM and EC risk among postmenopausal women and calculate the population attributable fraction of EC for different LNYM categories. Our study sample consisted of 117 589 women from the Norwegian Women and Cancer (NOWAC) Study...
May 21, 2018: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/29782310/putative-gonadotropin-releasing-hormone-agonist-therapy-and-dementia-an-application-of-medicare-hospitalization-claims-data
#2
Mark A Smith, Richard L Bowen, Richard Q Nguyen, George Perry, Craig S Atwood, Alfred A Rimm
BACKGROUND: Estrogen and hormone replacement therapies to reduce Alzheimer's disease (AD) have yielded conflicting results. However, this study proposes that the well-characterized increase in serum gonadotropins following menopause or andropause are accountable for the increased risk of developing AD among the elderly population. OBJECTIVE: To determine the role of gonadotropins in the development of AD and investigate gonadotropin-releasing hormone (GnRH) agonist therapy as a potential preventative and/or disease-modifying approach to AD management...
May 16, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29781874/extended-use-of-systemic-menopausal-hormone-therapy
#3
Andrew M Kaunitz
Because clinical trial data assessing more than 10 years of hormone therapy (HT) use are not available, providing guidance to menopausal women regarding duration of systemic HT is controversial. However, clinicians routinely encounter this issue in practice. Using available evidence and clinical experience, this chapter provides guidance for clinicians who care for patients who may be candidates for extended use of systemic HT.
May 17, 2018: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29779518/menopause-symptom-management-in-the-united-kingdom
#4
REVIEW
Debra Holloway
Menopause is a complex time in a woman's life. It is an increasingly a midlife event, when health care professionals should be aiming to optimize a woman's health for the next 30 years or so. Nurses need to be able to give up-to-date information and evidence for all forms of treatment based on a background of complex and ever-changing research. This article covers the main presenting complaints and treatments, from lifestyle to hormone replacement therapy, by drawing on guidelines from national bodies.
June 2018: Nursing Clinics of North America
https://www.readbyqxmd.com/read/29768475/conjugated-equine-estrogen-and-medroxyprogesterone-acetate-are-associated-with-decreased-risk-of-breast-cancer-relative-to-bioidentical-hormone-therapy-and-controls
#5
Zexian Zeng, Xia Jiang, Xiaoyu Li, Alan Wells, Yuan Luo, Richard Neapolitan
OBJECTIVE: By the 1990s it became popular for women to use hormone therapy (HT) to ease menopause symptoms. Bioidentical estrogen and progesterone are supplements whose molecular structures are identical to what is made in the human body, while synthetic supplements are ones whose structures are not. After the Women's Health Initiative found that the combined use of the synthetics conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) increased breast cancer risk, prescriptions for synthetic HT declined considerably...
2018: PloS One
https://www.readbyqxmd.com/read/29765929/gonadotropin-releasing-hormone-agonist-plus-aromatase-inhibitor-in-the-treatment-of-uterine-leiomyoma-in-near-menopause-patient-a-case-series-study
#6
Sanam Moradan
Objectives: There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of one of these two drugs. In this study as the first study decided to evaluate the effectiveness of the combination of GnRH agonists + aromatise inhibitor on the uterine fibroids. Methods: A cross-sectional prospective case series study was performed on 10 known cases of uterine fibroids late perimenopause, at least 3 myomas >5 cm, abnormal uterine bleeding and anemia due to fibroids, candidate for hysterectomy, no tendency to surgery...
April 2018: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/29764860/membrane-initiated-estrogen-receptor-signaling-mediates-metabolic-homeostasis-via-central-activation-of-protein-phosphatase-2a
#7
Kazutaka Ueda, Eiki Takimoto, Qing Lu, Pangyen Liu, Nobuaki Fukuma, Yusuke Adachi, Ryo Suzuki, Shengpu Chou, Wendy Baur, Mark J Aronovitz, Andrew S Greenberg, Issei Komuro, Richard H Karas
Women gain weight and their diabetes risk increases as they transition through menopause; these changes can in part be reversed by hormone therapy. However, the underlying molecular mechanisms mediating these effects are unknown. A novel knock-in mouse line with the selective blockade of the membrane-initiated estrogen receptor (ER) pathway was employed, and we found that the lack of this pathway precipitated excessive weight gain and glucose intolerance independent of food intake, and that this was accompanied by impaired adaptive thermogenesis and reduced physical activity...
May 15, 2018: Diabetes
https://www.readbyqxmd.com/read/29763969/hormone-replacement-therapy-for-women-previously-treated-for-endometrial-cancer
#8
REVIEW
Katharine A Edey, Stuart Rundle, Martha Hickey
BACKGROUND: Endometrial cancer is the sixth most common cancer in women worldwide and most commonly occurs after the menopause (75%) (globocan.iarc.fr). About 319,000 new cases were diagnosed worldwide in 2012. Endometrial cancer is commonly considered as a potentially 'curable cancer,' as approximately 75% of cases are diagnosed before disease has spread outside the uterus (FIGO (International Federation of Gynecology and Obstetrics) stage I). The overall five-year survival for all stages is about 86%, and, if the cancer is confined to the uterus, the five-year survival rate may increase to 97%...
May 15, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29763641/ischemic-stroke-across-sexes-what-is-the-status-quo
#9
REVIEW
Luca Liberale, Federico Carbone, Fabrizio Montecucco, Cathérine Gebhard, Thomas F Lüscher, Susanne Wegener, Giovanni G Camici
Stroke prevalence is expected to increase in the next decades due to the aging of the Western population. Ischemic stroke (IS) shows an age- and sex-dependent distribution in which men represent the most affected population within 65 years of age, being passed by post-menopausal women in older age groups. Furthermore, a sexual dimorphism concerning risk factors, presentation and treatment of IS has been widely recognized. In order to address these phenomena, a number of issue have been raised involving both socio-economical and biological factors...
May 12, 2018: Frontiers in Neuroendocrinology
https://www.readbyqxmd.com/read/29762148/menopausal-hormone-therapy-in-gynecologic-cancer-survivors-a-review-of-the-evidence-and-practice-recommendations
#10
Ekta Kapoor, Daniel Benrubi, Stephanie S Faubion
Gynecologic cancers are common in the United States and represent a significant health burden. Treatment of these cancers often causes premature cessation of ovarian function, with resultant symptoms that are often more severe than those associated with natural menopause. Hormone therapy is the most effective treatment for menopausal symptoms, but the decision-making process about its use can be complex for survivors of gynecologic cancer. In this review, we provide evidence-based recommendations about the use of hormone therapy after gynecologic cancer...
May 14, 2018: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29762147/managing-menopause-by-combining-evidence-with-clinical-judgment
#11
Chrisandra Shufelt, Joann Manson
In the United States, nearly 10 million women are currently in the menopause transition and 2.25 million women are 51 years of age, which is the average age of menopause. Approximately 75% of these women will experience vasomotor symptoms such as hot flashes and night sweats. Menopause hormone therapy (HT) remains the most effective treatment for menopausal symptoms, but the decision to use HT is complex and requires balancing the benefits and risks for the individual patient. The decision also requires clinical judgment and shared decision making with the patient...
May 14, 2018: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29753797/drug-development-for-brain-disorders-why-sex-matters-ischemic-stroke-across-sexes-what-is-the-status-quo
#12
REVIEW
Luca Liberale, Federico Carbone, Fabrizio Montecucco, Cathérine Gebhard, Thomas F Lüscher, Susanne Wegener, Giovanni G Camici
Stroke prevalence is expected to increase in the next decades due to the aging of the Western population. Ischemic stroke (IS) shows an age- and sex-dependent distribution in which men represent the most affected population within 65 years of age, being passed by post-menopausal women in older age groups. Furthermore, a sexual dimorphism concerning risk factors, presentation and treatment of IS has been widely recognized. In order to address these phenomena, a number of issue have been raised involving both socio-economical and biological factors...
May 10, 2018: Frontiers in Neuroendocrinology
https://www.readbyqxmd.com/read/29750683/hormone-therapy-in-breast-cancer-survivors-and-those-at-high-risk-for-breast-cancer
#13
Robert L Reid
Women and health care providers are often fearful of using hormone therapy to deal with distressing menopausal symptoms in circumstances where there is a perceived or real increased risk of breast cancer. This paper examines the evidence for and against hormone therapy use in 3 common clinical situations: the woman with a positive family history in a first-degree relative, the woman who has undergone risk-reducing salpingo-oophorectomy due to a known genetic mutation, and the woman in whom treatment of breast cancer has induced premature menopause...
May 10, 2018: Clinical Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29749272/fulvestrant-for-the-treatment-of-advanced-breast-cancer
#14
Sophie A Blackburn, Ruth M Parks, Kwokleung Cheung
The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy. Areas covered: This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment...
May 11, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29747269/-effect-of-low-dose-or-standard-dose-conjugated-equine-estrogen-combined-with-different-progesterone-on-bone-density-in-menopause-syndrome-women
#15
H L Zuo, Y Deng, Y F Wang, L L Gao, W Xue, S Y Zhu, X Ma, A J Sun
Objective: To explore the effect of low-dose or standard-dose conjugated equine estrogen (CEE) combined with natural progesterone or dydrogesterone on bone density in menopause syndrome women. Methods: Totally 123 patients with menopause syndrome were recruited and randomly assigned to 3 treatment groups: group A (low-dose CEE+progesterone) , group B (standard-dose CEE+progesterone) , group C (standard-dose CEE+dydrogesterone) . Using continuous sequential regimen, the duration of intervention was 12 cycles...
April 25, 2018: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/29739677/soy-isoflavones-improve-cardiovascular-disease-risk-markers-in-women-during-the-early-menopause
#16
T Sathyapalan, M Aye, A S Rigby, N J Thatcher, S R Dargham, E S Kilpatrick, S L Atkin
BACKGROUND: Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers. METHODS: The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months...
April 10, 2018: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29738420/vasomotor-symptoms-in-women-over-60-results-from-the-data-registry-on-experiences-of-aging-menopause-and-sexuality-dreams
#17
Paru S David, Juliana M Kling, Suneela Vegunta, Stephanie S Faubion, Ekta Kapoor, Kristin C Mara, Darrell R Schroeder, Karla Frohmader Hilsaca, Carol L Kuhle
OBJECTIVE: Frequency of vasomotor symptoms (VMS) in older women and the contributing factors are largely undefined. We measured the frequency of moderate-to-severe vasomotor symptoms (msVMS) in women ≥60 years of age and examined their characteristics to determine factors that may associate with VMS in older women. METHODS: A cross-sectional survey was completed using the Menopause Health Questionnaire from the Data Registry on Experiences of Aging, Menopause, and Sexuality...
May 7, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29738412/slco1b1-genetic-variation-and-hormone-therapy-in-menopausal-women
#18
Ann M Moyer, Mariza de Andrade, Stephanie S Faubion, Ekta Kapoor, Tanda Dudenkov, Richard M Weinshilboum, Virginia M Miller
OBJECTIVE: Response to menopausal hormone therapy (MHT) shows individual variation. SLCO1B1 encodes the OATP1B1 transporter expressed in the liver that transports many endogenous substances, including estrone sulfate, from the blood into hepatocytes. This study evaluated the relationship between genetic variation in SLCO1B1 and response to MHT in women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) at Mayo Clinic, Rochester, MN. METHODS: KEEPS participants were randomized to oral conjugated equine estrogen (n = 33, oCEE), transdermal 17β-estradiol (n = 33, tE2), or placebo (n = 34) for 48 months...
May 7, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29731984/hormone-replacement-therapy-decreases-the-risk-of-tinnitus-in-menopausal-women-a-nationwide-study
#19
Hsin-Chien Chen, Chi-Hsiang Chung, Vincent C F Chen, Yu-Chi Wang, Wu-Chien Chien
The incidence and risk of tinnitus associated with hormone replacement therapy (HRT) in menopausal women have not yet been fully examined. We examined the medical records of menopausal women aged between 45 and 79 years from Taiwan's National Health Insurance Research Database of records between 1 January 2000 and 31 December 2010 to establish matched cohorts (13,920 HRT users and 41,760 nonusers). The incidence of tinnitus in HRT users and nonusers were matched 1:3 based on propensity-score matching over this ten year period...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29730442/towards-optimization-of-estrogen-receptor-modulation-in-medicine
#20
REVIEW
Marie-Cécile Valéra, Coralie Fontaine, Marion Dupuis, Emmanuelle Noirrit-Esclassan, Alexia Vinel, Maeva Guillaume, Pierre Gourdy, Françoise Lenfant, Jean-François Arnal
Women now spend more than one-third of their lives in the postmenopausal years, and the decline of endogenous estrogen production during menopause is accompanied by a series of functional disorders that affect the quality of life. These symptoms could be alleviated or even totally suppressed by menopausal hormone therapy (MHT), initially based on natural estrogens extracted from the urine of pregnant mares (mainly in the USA, using the oral route) and later from the synthesis of the natural estrogen, 17β-estradiol (mainly in Europe, in particular using the transdermal route)...
May 3, 2018: Pharmacology & Therapeutics
keyword
keyword
85110
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"